Silencing of the metastasis suppressor RECK by RAS oncogene is mediated by DNA methyltransferase 3b-induced promoter methylation

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8413-8420

  Chang, Hui Chiu ^a,b   Cho, Chun Yu ^b   Hung, Wen Chun ^b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AZACITIDINE; DNA METHYLTRANSFERASE 3B; MEMBRANE PROTEIN; PROTEIN RECK; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL INVASION; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; HUMAN; HUMAN CELL; LUNG CANCER; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; CHROMATIN; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA, NEOPLASM; GENE SILENCING; GENES, RAS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 33749013323     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0685     Document Type: Article

References (50)

1. Grand RA, Owen D. The biochemistry of ras p21. Biochem J 1991;279:609-31.
2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
3. Bondy GP, Wilson S, Chambers AF. Experimental metastatic ability of H-ras-transformed NIH3T3 cells. Cancer Res 1985;45:6005-9.
4. Muschel RJ, Williams JE, Lowy DR, Liotta LA. Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol 1985;121:1-8.
5. Ichikawa T, Kiprianou N, Isaacs JT. Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. Cancer Res 1990;50:6349-57.
6. Takai Y, Takuya S, Tanaka K, Nakanishi H. Rho as a regulator of the cytoskeleton. Trends Biochem Sci 1995; 20:227-31.
7. Hughes DA. Control of signal transduction and morphogenesis by Ras. Semin Cell Biol 1995;6:89-94.
8. Khosravi-Far R, Der CJ. The Ras signal transduction pathway. Cancer Metastasis Rev 1994;13:67-89.
9. Hall A. Ras-related GTPases and cytoskeleton. Mol Biol Cell 1992;3:475-9.
10. Zhang Z, Vuori K, Wang H, Reed JC, Ruoslahti E. Integrin activation by R-ras. Cell 1996;85:61-9.
11. 1 integrin activation by Ha-Ras and R-Ras. J Biol Chem 2000;275:22590-6.
12. Schramm K, Krause K, Bittroff-Leben A, Goldin-Lang P, Thiel E, Kreuser ED. Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int J Cancer 2000;87: 155-64.
13. Schmidt CR, Washington MK, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS. Dysregulation of E-cadherin by oncogenic Ras in intestinal epithelial cells is blocked by inhibiting MAP kinase. Am J Surg 2003; 186:426-30.
14. Schmidt CR, Gi YJ, Coffey RJ, Beauchamp RD, Pearson AS. Oncogenic Ras dominates overexpression of E-cadherin in malignant transformation of intestinal epithelial cells. Surgery 2004;136:303-9.
15. Caulin C, Lopez-Barcons L, Gonzales-Garrigues M, et al. Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced Ha-ras oncogene products. Mol Carcinog 1996;15:104-14.
16. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
17. Pironin M, Clement G, Benzakour O, Barritault D, Lawrence D, Vigier P. Growth in serum-free medium of NIH3T3 cells transformed by the EJ-H-ras oncogene: evidence for multiple autocrine growth factors. Int J Cancer 1992;51:980-8.
18. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7: 728-35.
19. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
20. Himelstein BP, Lee EJ, Sato H, Seiki M, Muschel RJ. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene 1997;14: 1995-8.
21. Meade-Tollin LC, Boukamp P, Fusenig NE, Bowen CP, Tsang TC, Bowden GT. Differential expression of matrix metalloproteinases in activated c-ras-Ha-transfected immortalized human keratinocytes. Br J Cancer 1998; 77:724-30.
22. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
23. Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A 1998;95:13221-6.
24. Sasahara RM, Takahashi C, Noda M. Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun 1999;264:668-75.
25. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789-800.
26. Chang HC, Liu LT, Hung WC. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal 2004;16:675-9.
27. Liu HS, Scrable H, Villaret DB, Lieberman MA, Stambrook PJ. Control of Ha-ras-mediated mammalian cell transformation by Escherichia coli regulatory elements. Cancer Res 1992;52:983-8.
28. Pan MR, Hung WC. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 2002;277:32775-80.
29. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cell invasion. Cancer Res 2003; 63:3069-72.
30. Alemany R, Ruan S, Kataoka M, et al. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther 1996;3:296-301.
31. Zuber J, Tchernitsa OI, Hinzmann B, et al. A genome-wide survey of RAS transformation targets. Nat Genet 2002;24:144-52.
32. Soejima K, Fang W, Rollins BJ. DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene 2003;22: 4723-33.
33. Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 2004;23:3737-48.
34. Pruitt K, Ulku AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005;280:23363-70.
35. Kimura H, Nakamura T, Ogawa T, Tanaka S, Shiota K. Transcription of mouse DNA methyltransferase 1 (DNMT1) is up-regulated by both E2F-Rb-HDAC-dependent and independent pathways. Nucleic Acids Res 2003;31:3101-13.
36. Yanagisawa Y, Ito E, Yuasa Y, Maruyama K. The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochim Biophys Acta 2002;1577:457-65.
37. Milanini-Mongiat J, Pouyssegur J, Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J Biol Chem 2002;277:20631-39.
38. Merchant JL, Du M, Todisco A. Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun 1999;254:454-61.
39. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-31.
40. Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806-12.
41. Kim DH, Kim JS, Park JH, et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 2003;63:6206-11.
42. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002;1:599-606.
43. Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs 2003;4:1428-35.
44. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004;31:28-39.
45. Gelb MH, Scholten JD, Sebolt-Leopold JS. Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol 1998;2:40-8.
46. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000;20:138-48.
47. Law BK, Norgaard P, Moses HL. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J Biol Chem 2000;275: 10796-801.
48. Sebti SM. Protein farnesylation: implications for physiology, malignant transformation and cancer therapy. Cancer Cell 2005;7:297-300.
49. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005;45:629-56.
50. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004;22:4632-42.